TRPML1: calcium, autophagy, and a first candidate in the clinic

TRPML1 is a lysosomal Ca²⁺ release channel with an unusually broad mechanistic reach. One activation event is enough to trigger autophagosome-lysosome fusion, lysosomal exocytosis, and TFEB nuclear translocation, the master switch for lysosomal biogenesis and autophagy. Few lysosomal targets sit this centrally in the neuronal degradation machinery.

𝗪𝗵𝗲𝗿𝗲 𝗶𝘁 𝗳𝗮𝗶𝗹𝘀 𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝗳𝗼𝗹𝗹𝗼𝘄𝘀
Loss-of-function mutations in MCOLN1 cause Mucolipidosis type IV, establishing TRPML1 as essential for neuronal survival. Across Parkinson’s, Alzheimer’s, and ALS, the same pattern emerges: reduced channel activity, stalled autophagy, accumulating aggregates. Restoring it clears alpha-synuclein, reduces amyloid burden, and protects motor neurons under ER stress conditions.

𝗧𝗵𝗲 𝗳𝗶𝗲𝗹𝗱 𝗶𝘀 𝗺𝗼𝘃𝗶𝗻𝗴
Last month, Lysoway Therapeutics announced the Phase 1 dosing of LW-1017, a potent, brain-penetrant TRPML1 agonist designed to restore lysosomal function in neurodegeneration. The first TRPML1 agonist to enter the clinic.
With a candidate now in human trials, the pressure on the entire discovery chain increases. Mechanistic assays need to be more precise, screening closer to the actual target, in native lysosomal membranes. Whole-cell systems are no longer good enough to generate the SAR data this field now demands.

Reaching that level of precision is why at ORIA Bioscience we developed 𝐋𝐘𝐒𝐎-𝐏𝐫𝐞𝐩™.